Livforsakringsbolaget Skandia, Omsesidigt 13F: Cuts COR Stake by $10M
Key Points
- Livforsakringsbolaget Skandia lowered its position in Cencora, Inc. by 33,920 shares, leaving a total of 28,155 shares valued at roughly $8.45 million.
- Cencora shares recently traded around $343.27, sitting well above both their 50-day and 200-day moving averages ahead of upcoming November earnings.
- Wall Street analysts hold a consensus buy rating on Cencora with a mean price target of $367.67.
Get Cencora text alerts
We text you when insiders, Congress, analysts or big funds move on $COR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cencora, Inc. alert may contain errors. Disclosures
Livforsakringsbolaget Skandia trimmed its stake in Cencora, Inc. (NYSE:COR) during the quarter, according to a Form 13F filing with the U.S. Securities and Exchange Commission on October 21, 2026.
COR
Cencora, Inc.
What Changed in Livforsakringsbolaget Skandia's Cencora Position
The institutional investor cut its holdings by 33,920 shares, which translated to a 54.6% reduction. After the sale, the firm held 28,155 shares of the medical distributor. The remaining stake carried a reported value of $8,453,539 as of the filing date.
Other Institutional Activity in Cencora
Boston Partners grew its holdings by 385,970 shares, ending with 4,868,782 shares worth about $1,661,958,765 in its report dated June 30, 2026.
Cencora, Inc. Stock Up 0.1%
Cencora shares closed at $340.43 on October 21, 2026, and recently traded around $343.27 as of October 22, 2026, up about 0.8% since the filing. The stock sits below its 52-week high of $377.54 and above its 52-week low of $244.82. The share price is also trading above its 50-day moving average of $320.64 and its 200-day moving average of $317.50, reflecting steady momentum over the past several months.
Recent Earnings
Cencora reported trailing-twelve-month revenue of $332.77 billion and diluted earnings per share of $13.47. The next earnings report is scheduled for November 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
4 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 2.3%. Revenue missed estimates by 4.3%.
-
Profit surprise
EBITDA beat by 9 percent. Operating income met by 2 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
4 target cuts.
-
Earnings quality
Gross margin up 0.8 points. Positive free cash flow.
Earnings Call Summary
The company delivered a strong first quarter with 12 percent operating income growth and 9 percent earnings per share growth, driven by continued strength in specialty pharmaceuticals, particularly GLP-1 products which grew 11 percent. Management highlighted that US healthcare solutions performed at the high end of long-term guidance even excluding recent acquisitions like RCA and the newly closed OneOncology deal. The completion of the OneOncology acquisition marks a major strategic expansion of Cencora's managed service organization platform, which management views as a natural extension of its specialty pharmaceutical leadership.
Guidance Cencora raised full year revenue growth guidance to 7 to 9 percent from 5 to 7 percent, and operating income growth to 11.5 to 13.5 percent from 8 to 10 percent. The company closed its OneOncology acquisition and expects the MSO platform to drive meaningful operating income expansion this year and beyond.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Cencora pays an annual dividend of $2.40 per share, yielding 0.71% with a payout ratio of 17.4%.
Insider Buying and Selling at Cencora, Inc.
Company insiders executed several sales prior to the filing. Officer Elizabeth S. Campbell sold 11,300 shares on August 24, 2026, at an average price of $324.12. Officer Lazarus Krikorian sold 985 shares on September 1, 2026, and another 986 shares on October 1, 2026. Director Lon R. Greenberg sold 1,280 shares on September 16, 2026.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock, starting with RBC Capital reiterating its sector perform rating on September 8, 2026. Leerink Partners maintained an outperform rating on October 7, 2026, raising its target to $388. UBS maintained a buy rating on October 16, 2026, and Argus Research maintained a buy rating on October 20, 2026, lifting its target to $380.
About Cencora
Cencora is a healthcare company based in Conshohocken, Pennsylvania, that focuses on sourcing and distributing pharmaceutical products globally. It operates within the medical distribution sector, connecting drug manufacturers with healthcare providers.
Bottom Line
Investors will look toward Cencora's upcoming earnings report on November 4, 2026, for further updates on financial performance and distribution volume.
Related Filing Alerts
Source: Livforsakringsbolaget Skandia, Omsesidigt's 13F filing on $COR (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts